Actelion to enter Phase II clinical development with new dual orexin receptor antagonist in patients with insomnia - Yahoo Finance

Submitted by Anonymous (not verified) on Thu, 07/07/2016 - 05:10

Actelion to enter Phase II clinical development with new dual orexin receptor antagonist in patients with insomniaYahoo FinanceALLSCHWIL, SWITZERLAND - 07 July 2016 - Actelion Ltd (ATLN.VX) announced today that the company is initiating a Phase II program with its new dual orexin receptor antagonist (DORA) in patients with insomnia. The decision to move into a Phase II ...and more »